Latent autoimmune diabetes in adults (LADA) is a slowly developing form of autoimmune diabetes that appears in adults — usually after age 30 — and is often misdiagnosed as type 2 diabetes for months or years. Diagnosis requires a positive islet autoantibody (most often GAD-65) and no insulin requirement in the first six months. Studies suggest up to 10 percent of adults labeled with type 2 diabetes actually have LADA.
What Is LADA?
LADA was first described by Tuomi and colleagues in 1993 after researchers noticed that some adults diagnosed with type 2 diabetes carried the same autoantibodies seen in type 1 diabetes and progressed unusually quickly to insulin dependence. The condition has also been called type 1.5 diabetes, slowly progressive insulin-dependent diabetes, or latent type 1 diabetes — though LADA is the term most commonly used today.
In LADA, the immune system gradually destroys the insulin-producing beta cells of the pancreas. The destruction is slower than in classic type 1 diabetes — typically taking years rather than weeks or months — which is why patients usually do not present in acute ketoacidosis and can be managed without insulin at first.
Diagnostic Criteria
The most widely used criteria, proposed by the Immunology of Diabetes Society (IDS), require all three of the following:
- Age 30 years or older at diagnosis
- Presence of at least one circulating islet autoantibody — most commonly GAD-65, but also IA-2, ZnT8, or insulin autoantibodies
- No insulin requirement for at least the first six months after diagnosis
The American Diabetes Association’s Standards of Care recognize LADA within the broader category of autoimmune type 1 diabetes but acknowledge the distinct clinical course.
How LADA Differs from Type 1 and Type 2 Diabetes
| Feature | Type 1 Diabetes | LADA | Type 2 Diabetes |
|---|---|---|---|
| Typical age at onset | Childhood, adolescence, young adult | 30 or older | Usually 40 or older |
| Body habitus | Often lean | Often lean or normal weight | Often overweight or obese |
| Islet autoantibodies | Positive (multiple) | Positive (often GAD-65 alone) | Negative |
| Insulin resistance | Not central | Not central | Central feature |
| Time to insulin dependence | Weeks to months | Months to several years | Many years or never |
| Family history | Sometimes | May have autoimmune family history | Strong type 2 family history |
| C-peptide at diagnosis | Very low | Low-normal, falls over time | Normal or high |
| Risk of DKA at presentation | High | Low | Low |
Causes and Risk Factors
LADA is an autoimmune disease — the same broad mechanism as type 1 diabetes. The body’s immune system mistakenly targets beta cells in the pancreatic islets. Risk factors and contributors include:
- Genetic predisposition — HLA class II haplotypes (DR3, DR4) overlap with classic type 1 diabetes
- Family history of type 1 diabetes or other autoimmune conditions (thyroid disease, celiac, vitiligo)
- Environmental triggers — viral infections and other immune stressors have been proposed but not confirmed
- Possibly higher in populations of northern European ancestry, though LADA occurs worldwide
Unlike type 2 diabetes, obesity and sedentary lifestyle are not primary drivers of LADA, although they can worsen glycemic control when coexisting.
Symptoms
Early LADA symptoms are often subtle and indistinguishable from mild type 2 diabetes:
- Increased thirst and frequent urination
- Unexplained weight loss despite normal or increased appetite
- Fatigue
- Blurred vision
- Slow-healing cuts and frequent infections
- Numbness or tingling in hands or feet
Clues that may point toward LADA rather than typical type 2 diabetes include a lean body habitus, rapid loss of glycemic control on oral medications, a personal or family history of autoimmune disease, and early-onset diabetes in a non-obese adult. See our overview of symptoms of prediabetes for context on early glucose disturbance.
Diagnosis and Testing
Autoantibody Testing
- GAD-65 antibody — the most sensitive single test in adults; positive in 70 to 90 percent of LADA cases
- IA-2 (tyrosine phosphatase) antibody — less common but specific
- ZnT8 antibody — newer, useful when GAD is negative
- Insulin autoantibody — more useful in children
- Islet cell antibody (ICA) — older test, less commonly used today
C-Peptide
C-peptide is released alongside insulin in equimolar amounts and reflects residual beta-cell function. In LADA, fasting C-peptide is usually in the low-normal range at diagnosis and falls progressively. In type 2 diabetes, C-peptide is typically normal or elevated.
Who Should Be Tested
Autoantibody testing should be considered in adults diagnosed with type 2 diabetes who have one or more of the following features:
- Age under 50 at diagnosis
- BMI under 25
- Personal or family history of autoimmune disease
- Rapid progression to insulin requirement
- Poor response to oral medications despite good adherence
Treatment
Management aims to control blood glucose while preserving residual beta-cell function for as long as possible. Decisions about specific medications should be made with an endocrinologist.
Medications
| Class | Role in LADA |
|---|---|
| Metformin | Often first-line if some insulin secretion remains; addresses any insulin resistance |
| Sulfonylureas | Generally avoided — may accelerate beta-cell exhaustion by forcing insulin release |
| DPP-4 inhibitors | May modestly preserve beta-cell function in some studies |
| GLP-1 receptor agonists | Emerging evidence for beta-cell preservation; useful with some residual insulin |
| Insulin | Started early in LADA — basal first, then prandial as beta-cell function declines |
| SGLT2 inhibitors | Caution — higher DKA risk in insulin-deficient states |
Lifestyle
- Carbohydrate awareness and consistency support glucose control — review diet and nutrition guidance
- Regular physical activity improves insulin sensitivity
- Continuous glucose monitoring (CGM) is increasingly used in LADA to track variability
- Diabetes self-management education
Progression and Prognosis
Most people with LADA require insulin within 3 to 6 years of diagnosis, although the trajectory varies. Faster progression is associated with younger age at diagnosis, higher antibody titers, multiple positive antibodies, and lower C-peptide. Slower progression is associated with single low-titer antibody positivity, older age, and higher BMI.
Long-term complication risk in LADA is similar to type 1 and type 2 diabetes when glycemic control is comparable, making early identification and tight control important. See our guide on complications and related conditions for more.
Prevention
LADA cannot currently be prevented because it is autoimmune. Research into immune-modulating therapies — such as teplizumab in early type 1 diabetes — is ongoing and may eventually have a role in LADA. For now, prevention efforts focus on:
- Identifying high-risk individuals (family history, other autoimmune diseases) through monitoring
- Preserving residual beta-cell function once LADA is diagnosed
- Avoiding treatments that accelerate beta-cell loss
- Maintaining tight glycemic control to reduce complications
Related Reading
For more on diabetes subtypes and classification, see our companion guides on MODY, type 3c pancreatogenic diabetes, secondary diabetes, and our prediabetes basics hub. New monoclonal antibody therapies such as teplizumab are reshaping how early autoimmune diabetes is managed.
The Bottom Line
LADA is a slowly progressing autoimmune diabetes in adults that is frequently misdiagnosed as type 2 diabetes. Diagnosis hinges on adult age at onset, a positive islet autoantibody (usually GAD-65), and no insulin requirement in the first six months. Early identification matters because it changes treatment — sulfonylureas are generally avoided, while metformin, GLP-1 receptor agonists, and early insulin help preserve beta-cell function. If you have been diagnosed with type 2 diabetes but are lean, have a family history of autoimmune disease, or are progressing rapidly on oral medications, ask your doctor about GAD-65 antibody testing.
